These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 29601536)

  • 21. Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections.
    Reuter M; Kruger DH
    Virus Genes; 2020 Apr; 56(2):136-149. PubMed ID: 32036540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole.
    Abdelkader K; Gerstmans H; Saafan A; Dishisha T; Briers Y
    Viruses; 2019 Jan; 11(2):. PubMed ID: 30678377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteriophage inspired antibiotics discovery against infection involved biofilm.
    Fan X; Li W; Zheng F; Xie J
    Crit Rev Eukaryot Gene Expr; 2013; 23(4):317-26. PubMed ID: 24266847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bacteriophages: The promising therapeutic approach for enhancing ciprofloxacin efficacy against bacterial infection.
    Shariati A; Noei M; Chegini Z
    J Clin Lab Anal; 2023 May; 37(9-10):e24932. PubMed ID: 37377167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation and Characterization of Three Pseudomonas aeruginosa Viruses with Therapeutic Potential.
    Wang X; Tang J; Dang W; Xie Z; Zhang F; Hao X; Sun S; Liu X; Luo Y; Li M; Gu Y; Wang Y; Chen Q; Shen X; Xu L
    Microbiol Spectr; 2023 Jun; 11(3):e0463622. PubMed ID: 37125933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Multiwell-Plate Caenorhabditis elegans Assay for Assessing the Therapeutic Potential of Bacteriophages against Clinical Pathogens.
    Manohar P; Loh B; Elangovan N; Loganathan A; Nachimuthu R; Leptihn S
    Microbiol Spectr; 2022 Feb; 10(1):e0139321. PubMed ID: 35171008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of a genetically modified T7Select phage system to express the antimicrobial peptide 1018.
    Lemon DJ; Kay MK; Titus JK; Ford AA; Chen W; Hamlin NJ; Hwang YY
    J Microbiol; 2019 Jun; 57(6):532-538. PubMed ID: 31054139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy.
    Tagliaferri TL; Jansen M; Horz HP
    Front Cell Infect Microbiol; 2019; 9():22. PubMed ID: 30834237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Towards Inhaled Phage Therapy in Western Europe.
    Wienhold SM; Lienau J; Witzenrath M
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30909579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacteriophage genome engineering for phage therapy to combat bacterial antimicrobial resistance as an alternative to antibiotics.
    Usman SS; Uba AI; Christina E
    Mol Biol Rep; 2023 Aug; 50(8):7055-7067. PubMed ID: 37392288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phages Needed against Resistant Bacteria.
    Moelling K
    Viruses; 2020 Jul; 12(7):. PubMed ID: 32664292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacteriophages: an overview of the control strategies against multiple bacterial infections in different fields.
    Jamal M; Bukhari SMAUS; Andleeb S; Ali M; Raza S; Nawaz MA; Hussain T; Rahman SU; Shah SSA
    J Basic Microbiol; 2019 Feb; 59(2):123-133. PubMed ID: 30485461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy.
    Segall AM; Roach DR; Strathdee SA
    Curr Opin Microbiol; 2019 Oct; 51():46-50. PubMed ID: 31226502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biofilm control with natural and genetically-modified phages.
    Motlagh AM; Bhattacharjee AS; Goel R
    World J Microbiol Biotechnol; 2016 Apr; 32(4):67. PubMed ID: 26931607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacteriophages and Their Immunological Applications against Infectious Threats.
    Criscuolo E; Spadini S; Lamanna J; Ferro M; Burioni R
    J Immunol Res; 2017; 2017():3780697. PubMed ID: 28484722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacteriophages and phage-derived proteins--application approaches.
    Drulis-Kawa Z; Majkowska-Skrobek G; Maciejewska B
    Curr Med Chem; 2015; 22(14):1757-73. PubMed ID: 25666799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes.
    Green SI; Clark JR; Santos HH; Weesner KE; Salazar KC; Aslam S; Campbell JW; Doernberg SB; Blodget E; Morris MI; Suh GA; Obeid K; Silveira FP; Filippov AA; Whiteson KL; Trautner BW; Terwilliger AL; Maresso A
    Clin Infect Dis; 2023 Oct; 77(8):1079-1091. PubMed ID: 37279523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacteriophage and their lysins for elimination of infectious bacteria.
    O'Flaherty S; Ross RP; Coffey A
    FEMS Microbiol Rev; 2009 Jul; 33(4):801-19. PubMed ID: 19416364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing Phage Therapy That Overcomes the Evolution of Bacterial Resistance.
    Oromí-Bosch A; Antani JD; Turner PE
    Annu Rev Virol; 2023 Sep; 10(1):503-524. PubMed ID: 37268007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European regulatory aspects of phage therapy: magistral phage preparations.
    Verbeken G; Pirnay JP
    Curr Opin Virol; 2022 Feb; 52():24-29. PubMed ID: 34801778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.